The US, New Zealand and Mexican patent authorities have each issued composition of matter patents for a new family of peptides that Allon Therapeutics believes has the potential to be developed to treat neurological and neurodegenerative diseases. This new platform is derived from a protein involved in the function of microtubules that are critical to the correct structure and communication of neurons in the brain.
Individual peptides derived from this platform have shown memory improvement in mice with compromised cognition caused by the aggregation of the tau protein. One of the main functions of the tau protein is to stabilise microtubules and Allon's preclinical studies have shown that peptides from this new family have the potential to inhibit tau aggregation.
These patents cover a family of peptides comprising an entirely new class of compounds distinct from Allon's two existing neuroprotective technology platforms, activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF). The company's lead product candidate, davunetide, is based on ADNP.
Davunetide is being evaluated in a pivotal clinical trial as a potential treatment for progressive supranuclear palsy. Patient treatment has been completed in the multinational pivotal Phase II/III trial, and the company is on track to release top-line data from the clinical trial in the second half of December.